Neuland Laboratories

Neuland Laboratories Receivables

The Accounts Receivable of Neuland Laboratories (NEULANDLAB.NS) as of Nov 10, 2026 is 3.18 B INR. In the previous year, Accounts Receivable was 3.76 B INR — a change of -15.54% (lower).

Receivables

3.18 BINR

YoY

-15.54%

Last updated:

Accounts Receivable of Neuland Laboratories is 2025 3.18 B INR. Accounts Receivable of Neuland Laboratories was 2024 3.76 B INR. It decreases by -15.54% lower compared to the previous year.

The Neuland Laboratories Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
1.95 B INR
Jan 1, 2019
1.66 B INR
Jan 1, 2020
1.92 B INR
Jan 1, 2021
2.21 B INR
Jan 1, 2022
2.63 B INR
Jan 1, 2023
3.69 B INR
Jan 1, 2024
3.76 B INR
Jan 1, 2025
3.18 B INR
The Neuland Laboratories Receivables history
YEARReceivablesYoY
3.18 BINR-15.54%
3.76 BINR+2.07%
3.69 BINR+40.12%
2.63 BINR+19.26%
2.21 BINR+14.95%
1.92 BINR+15.80%
1.66 BINR-15.06%
1.95 BINR+7.73%
1.81 BINR+41.90%
1.28 BINR-0.85%
1.29 BINR+8.60%
1.19 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Accounts Receivable of Neuland Laboratories is 3.18 B INR in 2025.

Accounts Receivable of Neuland Laboratories changed from 3.76 B INR to 3.18 B INR, representing a -15.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Neuland Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neuland Laboratories

All Key Metrics — Neuland Laboratories